Cargando…
Tocilizumab in ICU-admitted COVID-19 Patients: A Retrospective Study
BACKGROUND: Severe and critically-ill COVID-19 patients are characterized by a severe inflammatory response. Pharmacologic inhibition of acute-phase inflammatory pathways such as IL-6 receptor inhibitor, Tocilizumab (TCZ) may improve patient outcomes in these cases. Consequently, the therapeutic ben...
Autores principales: | Siami, Zeinab, Hedayat Yaghoobi, Mojtaba, Karimi, Parsa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iran University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657263/ https://www.ncbi.nlm.nih.gov/pubmed/38021396 http://dx.doi.org/10.47176/mjiri.37.92 |
Ejemplares similares
-
Investigation of microbial coinfection in 453 septic COVID-19 patients admitted to hospital; a retrospective study
por: Khavandegar, Armin, et al.
Publicado: (2023) -
Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
por: Elhazmi, Alyaa, et al.
Publicado: (2023) -
Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study
por: Moes, Dirk Jan A. R., et al.
Publicado: (2021) -
Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial
por: Siami, Zeinab, et al.
Publicado: (2021) -
Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study
por: Ibrahem, Hoda Younes, et al.
Publicado: (2022)